Log In

 
Company : Boehringer Ingelheim 
Thursday, June 30, 2016 4:05PM IST (10:35AM GMT)
 
(BW)(BOEHRINGER-INGELHEIM)
INMARKTM now enrolling: first study to evaluate the effect of OFEV® (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients
First time the effect of OFEV® is being explored on change of biomarkers reflecting the fibrotic process in the lungsINMARK™ will assess whether temporal changes in these biomarkers can predict the clinical course of IPF earlierIdentifying biomarkers to predict the clinical course of IPF early in individual patients remains one of the most important challenges to improve overall patient management
 
Ingelheim, Germany

Boehringer Ingelheim today announces that the first patient has been enrolled in a new study, INMARK™, investigating the effect of OFEV® (nintedanib) on changes in specific blood biomarkers. These changes in biomarkers indicate the excessive scarring (fibrosis) in the lungs of patients with idiopathic pulmonary fibrosis (IPF).

 

Biomarkers are measurable indicators of the presence or severity of a condition and used to monitor and predict the disease course of patients so that appropriate treatment can be planned. INMARK™ will measure changes in various extracellular matrix (ECM*) turnover biomarkers already shown to predict disease progression in IPF patients. ECM turnover is part of healthy tissue maintenance. However uncontrolled or excessive turnover is a key driver for the structural changes seen in IPF lungs, leading to progressive scarring and loss of lung function.

 

IPF is a debilitating and fatal lung disease with a high mortality, which causes permanent scarring of the lung tissue and loss of lung function over time.Early initiation of treatment may be crucial to help slow disease progression. Recent advancements have been made in the management of IPF with the availability of specific antifibrotic drugs such as OFEV®, which has been shown to slow disease progression by approximately 50% across three key studies. However despite these advances, physicians are still uncertain when to start treatment in individual patients. This is due to the unpredictability and differences in disease progression across patients with IPF and the lack of biomarkers to inform how the disease will progress in individual patients and who may respond best to treatment.

 

“The initiation of this new study marks a major milestone. The trial is of great scientific value in that it will provide better understanding of IPF and the value of nintedanib treatment in individuals with preserved lung function. Importantly this is the first time we are investigating the effect of any antifibrotic treatment on changes in specific biomarkers in IPF,” commented Dr Toby Maher, Consultant Respiratory Physician at the Royal Brompton Hospital in London, United Kingdom and principle investigator. “Being able to identify biomarkers that will predict how the disease will progress in a specific patient will allow physicians to start their patients on appropriate treatment at the earliest opportunity to help slow disease progression. It remains one of the most urgent challenges for effective management for IPF patients.”

 

Early diagnosis of IPF is critical to helping patients manage their condition. The median survival of IPF patients following diagnosis is just 2-3 years, underlining the importance of early and accurate diagnosis and the vital role of treatments to help slow disease progression. OFEV® has been shown to slow disease progression with approximately 50% reduction in the decline of lung function across a broad range of IPF patient types.

 

Dr William Mezzanotte, Therapy Area Head, Respiratory Medicine, Boehringer Ingelheim, said: “In a disease that displays variable rates of progression, identification of biomarkers that could allow physicians to identify and monitor individual disease progression and treatment successes in patients with IPF is essential. We hope that the identification of these biomarkers, particularly early in the disease, has the potential to improve overall patient management and enable better delivery of patient care.”

 

INMARK™ is one of a number of new trials recently initiated by Boehringer Ingelheim to provide the scientific community with important information on the safety and tolerability of OFEV® in combination with other drugs and across different patient populations. This is part of Boehringer Ingelheim’s continued commitment to tackling the global burden of progressive fibrotic lung diseases.

 

* The ECM is the network of proteins and carbohydrates that surround a cell and is part of all living tissues. As well as providing structural support for cells, the ECM supports a tissue’s division, growth and development.ECM turnover is part of healthy tissue maintenance. Assessment of ECM turnover may serve as biomarkers for disease activity and progression in IPF.

 

~ ENDS ~

 

Please click on the link below for ‘Notes to Editors’ and ‘References’:

 

http://www.boehringer-ingelheim.com/press-release/ipf-ofev-inmark-biomarker-trial

 

Intended audiences:

 

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

 

 

 

 

 
For News Release background on Boehringer Ingelheim click here
 
Media Contact Details
CONTACTS : Boehringer Ingelheim Corporate Communications Media + PR Anja Konschak 55216 Ingelheim/Germany Phone: +49 6132 – 77 182415 Fax: +49 6132 – 77 6601 Email: press@boehringer-ingelheim.com
 
 
Submit your press release
More News from Boehringer Ingelheim

22/06/2017 11:20AM

New data reveal high rates of stroke history in asymptomatic atrial fibrillation patients

Boehringer Ingelheim today announced findings from GLORIA™-AF which show that people with non-valvular atrial fibrillation (AF) with few or no symptoms are more likely to have had a stroke prior to AF diagnosis ...

14/06/2017 7:57PM

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

Boehringer Ingelheim announced today results from the pivotal Phase III VOLTAIRE®-RA1 study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and ...

05/06/2017 9:50PM

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017

Boehringer Ingelheim today announced that Phase II results from LUME-Meso, a randomised, double-blind, placebo-controlled trial, have been presented as part of an Oral Abstract Session at the 2017 Annual Meeting of the ...

Similar News

27/06/2017 7:14PM

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the Phase 3 ECHELON-1 clinical trial met its primary endpoint of a statistically significant improvement in ...

No Image

27/06/2017 7:02PM

Takeda and Biological E. Limited Announce Partnership to Develop Low-Cost Combination Vaccines for Low- and Middle-Income Countries around the Globe

Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) and Biological E. Limited (“BE”) announced that they have entered into a collaboration whereby two licensing agreements to ...